Bitcoin fell sharply below $69,000, dropping to around $67,800 on Binance, marking a 9% weekly loss and triggering over $1.6 billion in liquidations mostly on long positions. The market faces extreme fear with the Fear & Greed index at 20, driven by capital outflows from Bitcoin ETFs and a sharp decline in stablecoin supply, reducing liquidity and demand. This downturn pressures investors and could lead to further declines unless capital returns and liquidations stabilize. Other major cryptocurrencies like Ethereum and Solana also declined, signaling broader market weakness.
Bitcoin's recent price drop to $67,500 and $1.6 billion in liquidations provide context for readers. For those following the broader cryptocurrency market, 12 out of 50 major cryptocurrencies on Pluang rose while 37 fell as of Nov 13, 2026 17:21 WIB. Notable movers include CAKE at Rp31.346 with a 4.69% decline, AAVE at Rp2.021.122 down 4.50%, and BNB at Rp11.643.523 falling 4.34%.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
